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Abstract 
Background: A sentinel lymph node (SLN) biopsy is an interesting issue in the field of surgical oncology and 
has recently been introduced to the treatment of gastric cancer. The purpose of this study is to assess accuracy, 
sensitivity, specificity, and false negative rates (FNRs) of SLN biopsies, and to ascertain whether or not this 
procedure is useful for locally advanced gastric cancer. 
Methods: From December 2013 to March 2014, 22 patients with gastric cancer were enrolled in this study. 
After laparotomy, patent blue was injected around the tumor subserosaly, resection was then done, and SLNs 
were detected on a back table. Afterward, D2 dissection was carried out. Finally, SLNs and other specimens 
were submitted for permanent pathology. 
Results: SLNs were detected in 20 of 22 patients. The total number of SLNs was 87. SLNs were positive in 
7 patients, and the total number of positive SLNs was 17. In three patients, the SLNs were negative, whereas 
other LNs were positive, with an FNR of 15%. 18 patients received neoadjuvant. Complete pathologic 
responses with negative LNs were seen in 3 patients. Accuracy, sensitivity, specificity, and negative predictive 
values were 80%, 66%, 90%, and 76%, respectively.
Conclusions: This research demonstrated that SLN mapping in advanced gastric cancer is an appropriate 
method with acceptable levels of accuracy, sensitivity, and negative predictive values, even in those patients 
who received neoadjuvant treatment. 
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Introduction
Gastric adenocarcinoma is the fourth most prevalent 
form of cancer worldwide, and the second most lethal 
cancer. Lymphatic spread is a form of distribution of 
gastric cancer, and one of the most important 
prognostic factors is the involvement of lymph nodes 
(LNs) and the number of LN metastases. Surgery and 
LN dissection are standard treatments of gastric 
adenocarcinoma. An extensive LN dissection has a 
better survival rate; thus, D2 dissection seems to 
achieve better results than D1 dissection. However, D2 
dissection is slightly more complicated, even for 
experienced surgeons (1-8). Hence, a technique that 
predicts nodal involvement can help in deciding on the 
type of LN dissection to perform (3). Pre-operative 
modalities for the detection of metastatic LNs in gastric 
cancer have a very low sensitivity (9,10). The sentinel 
LN (SLN) is the first LN that receives drainage from 
the primary tumor. Based on SLN theory, LN 
dissection will be limited when there is no metastasis in 
the SLN (4,5,10-12). 
SLN seems to be a reliable method that is able to 
determine the presence or absence of metastasis in LNs 
with high accuracy (12). SLN was proposed for parotid 
malignancy by Gould et al. (13) in 1960. Cabanas (14) 
used this concept in penile cancer in 1977 but it was 
not practiced until 1992, when Morton et al. (15) 
developed SLN biopsy in malignant melanoma. 
Afterward, this concept was widely used for breast 
cancer. Palaia et al. (16) used the SLN concept for 
gastric cancer in 1999; then, Japanese surgeons vastly 
used SLN biopsy in gastric cancer. The application of 
SLN mapping in gastric cancer is a more difficult than 
breast carcinoma and malignant melanoma because the 
lymphatic stream of the stomach is much more 
complicated (7,11,17). There are promising studies of 
SLN biopsies in early gastric cancer, particularly in 
Japan. The objective of this study is to evaluate the 
accuracy, sensitivity, and specificity of the SLN 
mapping of gastric adenocarcinoma in Iran, where the 
majority of patients are at locally advanced stages. 
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of P < 0.05 was considered significant. The SPSS 
version 20 (SPSS Inc., Chicago, IL, USA) was used.  
Results 
Among the 22 patients, SLNs were not detected in  
2 patients. The detection rate (DR) was 90.9%. One of 
the two patients was a 41-year-old man suffering from 
cancer of the proximal third, with a tumor of 6 cm in 
size and clinical stage of cT3N0. His pathologic type 
was signet-ring, with 6 positive LNs out of 7; all 
positive LNs were at Level I. The another patient was a 
66-year-old man with a tumor size of 4 cm in the
middle third of his stomach and a clinical stage of
cT4N2, his pathologic type was also signet-ring. 22 LNs
were dissected from which 2 were positive in Level II.
Of 20 eligible patients, 19 were male and 1 was 
female. The average age [± standard deviation (SD)] 
was 61.9 (± 8.9) years ranged from 43 to 80. From 18 
patients who had pre-operative EUS, 2 patients had a 
clinical stage of cT2 (11.1%), 14 patients had cT3
(77.7%), and 2 patients had cT4 (11.1%). Mean tumor 
size (± SD) was 4.15 (± 2.0) cm with a range of 1.5-10 
cm. Eight tumors (40%) were located on the upper
third of the stomach, 5 (25%) were on the middle third
and 7 (35%) were on the lower third. 13 patients 
underwent a total gastrectomy, and 7 had a partial 
gastrectomy. Altogether, 451 LNs were harvested, with
a mean of 22.5 LNs for each patient and a range of
6-42. 87 SLNs were detected with a mean of 4.3 SLNs
per patient and a range of 1-9 per patient. Seven
patients (35%) had positive SLNs and altogether,
17 SLNs were positive and were all Level I (Table 1).
Table 1. Characteristics of the patients 
Total number patients 20 
Sex (male/female) 19/1 
Age (years) 61.9 (range 43-80) 
Tumor location 
Upper third 8 
Middle third 5 
Lower third 7 
Gastric resection 
Total gastrectomy 13 
Partial gastrectomy 7 





Tumor size (cm) 4.15 (range1.5-10) 
Number of retrieved LN 451 (range 6-42) 
Number of retrieved SLN 87 (range 1-9)
Number or retrieved positive SLN 17 (range 1-5) 
Number of patients with positive SLN 7 
SLN: Sentinel lymph node, LN: Lymph node
Materials and Methods 
From December 2013 to March 2014, 22 patients with 
primary gastric adenocarcinoma, whose disease was 
confirmed by endoscopic biopsy and were medically fit 
for surgery, were selected for this study. They had been 
referred to the Department of Surgical Oncology of the 
Cancer Institute of Tehran, Iran, and were enrolled in 
the cross-sectional study of an SLN biopsy. All patients 
were scheduled for gastrectomy and D2 
lymphadenectomy with curative intent. This study was 
approved by the Institutional Review Board and 
Committee of Tehran University, and pre-operative 
informed consent was obtained from patients.  
Clinical studies and staging included: 
esophagogastric endoscopy and biopsy, endoscopic 
ultrasonography (EUS), chest and abdominopelvic 
computed tomography-scans, and preoperative 
laparoscopy for T3 or N1 tumors. Exclusion criteria 
were liver metastasis, peritoneal seeding, nodal 
involvements at Level III and IV, involvement of 
celiac, superior mesenteric, and left gastric arteries. 
Age, tumor depth, tumor size, and neoadjuvant therapy 
were not the exclusion criteria in this study. 
After laparotomy via an upper midline incision, the 
abdominal cavity was carefully explored in order to 
assess tumor resectability and metastases. The patients 
were excluded from the research when the 
aforementioned exclusion criteria were met. The 
gastrocolic ligament was then opened and the lesser sac 
was entered and the tumor was identified by palpation. 
Before any dissection, 0.5 cc of patent blue was 
injected subserosaly (SS) at four points around the 
tumor with a 25-gauge needle. Unlike breast cancer, 
massage of the injection site of the dye was not done. 
Then, gastric cancer and perigastric LNs were resected. 
Total gastrectomy was performed for the tumors 
located at the upper and middle parts of the stomach, 
and partial gastrectomy was performed for those at the 
lower part. The dissecting specimens were then 
investigated for assessing the number and situation of 
blue LNs that were considered to be SLNs on the back-
table. The LNs locations were described using 
Japanese Classification of Gastric Carcinoma (18). The 
operations continued to perform a D2 dissection, and 
finally, stained blue LNs, which had been isolated on 
the back-table, the tumor was resected along with the 
stomach. The D2 dissected specimens were separately 
submitted for permanent pathology. 
The frozen section was not performed on SLNs. 
SLNs and non-SLNs were fixed in formalin and were 
engulfed in paraffin. Then, all LNs were sliced for 
routine hematoxylin and eosin (H and E) stains. 
Sensitivity, specificity, positive predictive value, 
and negative predictive value with a 95% confidence 
interval were calculated. The chi-square test was 
applied to assess differences in proportions and a value 
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Figure 1. Relationship between status of sentinel lymph node (SLN) and non-SLN 
Table 2. Value of sensitivity, specificity, negative predictive value and positive predictive value
Statistics parameters Estimated value (%) 95% confidence interval (CI)
Sensitivity 66 23-67
Specificity 90 57-99
Negative predictive value 76 45-93
Positive predictive value 85 42-99
In six out of the seven patients with metastatic 
SLNs, metastases were also found in non-SLNs. For 
one patient with a positive SLN, metastasis was not 
seen in non-SLN. Accuracy and positive predictive 
values were 80% and 85%, respectively. 
There were 3 patients with negative SLNs, whereas 
non-SLNS positive rates and false negative rates 
(FNRs) were 15%. One of the three patients had tumor 
on the upper third of his stomach at a size of 5 cm.  
28 of his LNs were dissected, 8 of which were SLNs 
and of these, 3 were non-SLNs positive as one of them 
was at Level II. The second patient had a 3 cm tumor 
on the middle third of his stomach, from which 31 LNs 
were retrieved. 7 of these were SLNs and 6 were non-
SLNs positive, and three of them were at Level II. The 
third patient had a 3.5 cm tumor located on the lower 
third. 11 LNs were determined, with one SLN and one 
non-SLN positive at Level I. The pathologic grade of 
all the patients was G2.  
Of the 20 eligible patients, 18 had EUS and 
received neoadjuvant therapy and the 2 other patients 
had no pre-operative EUS or neoadjuvant therapy. In 
3 patients (15%), tumors were not seen by a pathologist 
due to neoadjuvant-induced regression. The 
relationship between the status of SLN and non-SLN of 
patients is summarized in figure 1. 
Based on the chi-square test, there is a significant 
correlation between the status of SLN and non-SLN 
patients (P < 0.05). Furthermore, sensitivity, 
specificity, and negative predictive values are 
acceptable (Table 2). 
Discussion 
At the beginning of the 21st century, a SLN biopsy was 
considered as a method for gastric cancer surgery 
(19-21). The aim of the SLN biopsy is to facilitate 
sufficient resection while reducing the risk of 
morbidity related to unnecessary excision of LNs (3).  
To determine SLN, a tracer is needed which must 
be: easily available, non-toxic, cheap, quickly clearable 
from the injection site, and rapidly accumulated in 
SLNs. It must also flow slowly from SLNs to other 
LNs and be easily recognizable by the surgeon without 
using sophisticated tools. There are currently no tracers 
that possess all of these traits. Two tracers are routinely 
used at present, dye and radioisotope. Dye agents used 
include: isosulfan blue, patent blue, and indocyanine 
green. 99m radiolabeled tin colloid is frequently used as 
the radio isotope (2,3).  
The advantages of dye-guided tracers include ease 
of use, cost-effectiveness, and real-time observation of 
lymphatic drainage. However, in dense fat, stained LNs 
are not visible. Radio-guided tracers should be injected 
a day before the operation with the endoscopy 
submocusaly, which is a slightly invasive procedure. 
Due to the proximity of SLNs to the primary tumor, a 
shine-through effect distorts the detection of SLNs and 
is also expensive. It is not available in many clinics, 
but it can detect LNs even in dense fat (2,3,5,6,22,23). 
SLN was detected 
n = 20 
SLN was not detected
n = 2 
Negative SLN
n = 13 
Positive SLN




n = 6 
Negative non-SLN
n = 1 
Positive non-SLN 
n = 3 
Enrolled patients 
n = 22
Is the Lymph Node Biopsy Useful in Gastric Cancer? 
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Some authors merely used dye or radioisotopes, while 
others used a combination of both. There were no 
differences between dye-guided and radio-guided 
tracers in DRs and accuracy but it was reported that 
dual-guided methods are superior (2,12,24). We used 
only patent blue because it was cost-effective, available 
in our operation room and easy to use.  
There are two types of injection methods for the 
tracer: submucosa (SM) and SS. SM injection is done 
by an endoscopy, 1 day before surgery in radio-guided 
methods, or immediately before operation in dye-
guided methods. The latter method is a difficult 
technique due to the supine position and incorporation 
of general anesthesia, as well as endotracheal 
intubation, which makes endoscope insertion more 
complicated. It also seems that the injection of tracers 
by endoscope around lesions that are within the pylorus 
is not technically easy. Furthermore, it requires a 
theater equipped with an endoscopic instrument 
(2,3,12). SS injection, which is done by the surgeon in 
the operating room, is convenient, time-saving and 
needs no specific tool. However, it is not useful for 
non-palpable tumors (5,6,25). Some authors directly 
compared SM with the SS technique and concluded 
that, statistically speaking, there is no difference 
between the two methods (25-27). It seems that 
accurate injection of the tracers around the tumor, 
rather than the type of injection, is essential for 
identifying SLNs (2). In this study, the SS procedure 
was applied on account of its ease of use.  
The majority of researchers that used dye defined 
SLN as all the LNs stained within 5-20 minutes of the 
dye injection (4,6,7,23,28,29). Lee et al. (30) and Miwa 
et al. (31) dissected SLNs after a resection of the 
stomach on a back-table. In the present research, the 
researchers also determined SLNs on the back-table 
after gastric resection. Ishizaki et al. (32) stated that the 
time interval from injection to dissection of stained-
LNs altered the FNR and accuracy as the time became 
longer, it resulted in an FNR decrease and an accuracy 
increase. 
DR of SLN mapping varies from as high as 100% 
in Arigami et al. (33), Hayashi et al. (34), and Wang et 
al. (35) series to as low as 74% in the Simsa et al. (36) 
series. In this work, DR was 90.9% (20/22). Cozzaglio 
et al. (4) and Ryu et al. (6) stated that DR decreased in 
the upper third of the stomach because of the dense fat 
that hinders the SLNs. In this study, we did not find 
this to be an issue. Accuracy, sensitivity, and 
specificity were, respectively, 80%, 66%, and 90% in 
our research. Mochiki et al. (10) and Kelder et al. (23) 
stated that an increase of tumor depth could lead to a 
decrease in SLN DRs and an increase of FNR, 
presumably due to tumor deposits that occluded the 
lymphatic drainage. FNR is the most important factor 
in SLN techniques and can result in local control 
failure (11). In our theme, FNR was 15%. We could 
not find correlations between the characteristics of 
patients and FNR. Lee et al. (37) mentioned that a 
sufficient number (> 3) of SLNs are needed to prevent 
FNR. We harvested 87 SLNs from 20 patients with a 
mean of 4.3 per patient and range from 1 to 9 per 
patient. Su et al. (5), Isozaki et al. (28), Song et al. (29) 
and Miyashiro et al. (38), respectively, reported 2.8, 
3.3, 2.7 and 3.8 SLNs per patient. 
Complexity and multi-directionality of lymphatic 
drainage of the stomach can lead to skip metastasis in 
gastric cancer. It implies that metastasis at Level II is 
without the involvement of Level I LNs. Skip 
metastasis is a challenge in SLN tactics in gastric 
cancer that can increase FNR (7,11,17,30). Miwa et al. 
(31) and Ajisaka and Miwa (39) mentioned that the 
skip metastases and metastases in non-SLNs were 
usually found in the same lymphatic basin of the SLNs.
Based on this concept, Miwa et al. (31) divided
lymphatic flows of gastric cancer into five sections
according to their location along with major arteries as
follows: left gastric artery, right gastric artery, left
gastroepiploic artery, right gastroepiploic artery, and
posterior gastric artery. Takeuchi and Miwa (12)
therefore recommended that the entire lymphatic basin
of SLNs should be dissected instead of the removal of 
the identified SLNs (pick-up method). Lee et al. (40)
showed that lymphatic basin dissection (LBD) is
superior to the pick-up procedure in the detection of
SLNs metastases. We performed the pick-up technique 
because LBD is indeed a limited lymphadenectomy as
well as a time-consuming option.
Skip metastasis was stated to be 1.4% in early 
gastric cancer (31). Su et al. (5) reported 9.6%, Kim et 
al. (41) mentioned 17%, and Lee et al. (30) stated 
21.6% of skip metastasis in their researches. In this 
study, skip metastasis only occurred for one patient, 
whose SLNs were not detected, as a result, skip 
metastasis was calculated to be 4.5%. Huang et al. (7) 
addressed no clinicopathologic factors to be associated 
with skip metastasis. Although the decrease of survival 
chance was shown in the patient with skip metastasis, 
there were no statistically significant differences. 
Research carried out by Lee et al. (30) showed that 
tumor size was associated with skip metastasis, but the 
tumor differentiation and depth did not relate to skip 
metastasis. He also reported that skip metastasis 
occurred in advanced gastric cancer because the 
lymphatic system was blocked by tumor emboli. 
Yasuda et al. (42) stated that a gastric tumor with a 
diameter of 5 cm or lower is appropriate for SLN 
biopsy. Thus, the majority of SLN mapping research in 
gastric cancer was planned for tumors below 5 cm in 
size. Lee et al. (30) also reported that the most common 
regions for skip metastasis are station numbers 7, 8, 
and 9. Thus, if SLNs were not determined in Level I, 
station numbers 7, 8 and 9 should be dissected to 
diminish the skip metastasis and FNR. 
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Isozaki et al. (43) reported that serial sectioning of 
SLNs could result in the increase of the accuracy rate.
We only sliced one section of the SLNs as serial 
sectioning was time-consuming and was not routine in 
the many pathologic laboratories. Some authors used 
immunohistochemistry and reverse transcriptase 
polymerase change reactions for increasing the 
accuracy of SLNs but it should be considered that these 
techniques are sophisticated, expensive, and time-
consuming and are available only in a minority of 
hospitals. These procedures usually determine micro 
metastasis and isolated tumor cells that are not 
diagnosed with routine H and E stains (33,44,45). 
These entities are controversial in gastric 
adenocarcinoma treatments and prognosis (12). 
Based on the Japanese Gastric Cancer Association 
guidelines (46), there is no place for neoadjuvant 
therapy in gastric cancer treatment, even at advanced 
stages. Hence, in Japanese articles on SLN biopsies in 
gastric cancer, neoadjuvant therapy was not used. In 
research conducted in western countries, it is not 
clearly reported whether neoadjuvant therapy was 
applied or not (4,17). Based on the MAGIC trial (47), 
we used perioperative chemotherapy for the treatment 
of advanced gastric cancer. In this study, neoadjuvant 
therapy led to complete pathologic responses of tumors 
and negative LNs in 3 patients. It seems that 
neoadjuvant therapy can distort the integrity of LN 
architecture and may interfere with detection of LN 
metastasis. Thus, if neoadjuvant is used for gastric 
cancer, the SLN biopsy is in doubt (17). However, in 
this study, SLN mapping was not affected by 
neoadjuvant treatment.
Conclusion 
As similar to the acceptable results of SLN mapping in 
early gastric cancer, it seems that this technique is 
feasible in advanced gastric cancer and the modern 
approach of neoadjuvant treatment for it. However, 
further evaluations are required to introduce the SLN 
concept in locally advanced gastric cancer treatments 
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